Literature DB >> 11334892

Human immunodeficiency virus and assisted reproduction: reconsidering evidence, reframing ethics.

A D Lyerly1, J Anderson.   

Abstract

OBJECTIVE: To review the advances in the treatment of human immunodeficiency virus (HIV) infection and revisit the medical, ethical, and legal issues surrounding infertility management in HIV-infected couples.
DESIGN: Analytic review. RESULTS(S): HIV infection continues to be a serious public health and reproductive issue. However, present policies which allow for the categorical exclusion of HIV-infected individuals from infertility services should be reconsidered in light of improvements in the prognosis of infected individuals and a dramatic decrease in the risk of vertical transmission. An analysis of the ethical cogency of the arguments against the provision of services does not substantiate the exclusion of HIV-infected individuals; rather, the principle of justice requires that HIV-infected women be treated the same way as a woman who might have an increased risk of conceiving a child with a disability or a may have a decreased life expectancy due to a chronic illness such as diabetes. Ethical disagreement notwithstanding, with the precedents recently established by the Americans with Disabilities Act (ADA), discrimination based on HIV status would also likely be unlawful under most circumstances. CONCLUSIONS(S): With advances in the treatment of HIV infection, contextualized counseling and a respect for patients' decisions regarding infertility treatment should be adopted as public policy. It is neither ethically nor legally justifiable to categorically exclude individuals from infertility services on the basis of HIV infection.

Entities:  

Keywords:  Genetics and Reproduction; Health Care and Public Health

Mesh:

Year:  2001        PMID: 11334892     DOI: 10.1016/s0015-0282(01)01700-9

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  8 in total

Review 1.  Should HIV discordant couples have access to assisted reproductive technologies?

Authors:  M Spriggs; T Charles
Journal:  J Med Ethics       Date:  2003-12       Impact factor: 2.903

Review 2.  Use of assisted reproductive technology to reduce the risk of transmission of HIV in discordant couples wishing to have their own children where the male partner is seropositive with an undetectable viral load.

Authors:  H W G Baker; A Mijch; S Garland; S Crowe; M Dunne; D Edgar; G Clarke; P Foster; J Blood
Journal:  J Med Ethics       Date:  2003-12       Impact factor: 2.903

Review 3.  The physician as an accessory in the parental project of HIV positive people.

Authors:  Guido Pennings
Journal:  J Med Ethics       Date:  2003-12       Impact factor: 2.903

4.  Feasibility of Repurposing the Polyanionic Microbicide, PPCM, for Prophylaxis against HIV Transmission during ART.

Authors:  Robert A Anderson; David Brown; Erin M Jackson; Kenneth A Feathergill; James W Bremer; Ralph Morack; Richard G Rawlins
Journal:  ISRN Obstet Gynecol       Date:  2010-11-28

5.  Provider attitudes about childbearing and knowledge of safer conception at two HIV clinics in Malawi.

Authors:  Paul Kawale; Deborah Mindry; Ann Phoya; Perry Jansen; Risa M Hoffman
Journal:  Reprod Health       Date:  2015-03-07       Impact factor: 3.223

6.  Reproductive rights and options available to women infected with HIV in Ghana: perspectives of service providers from three Ghanaian health facilities.

Authors:  Amos Kankponang Laar
Journal:  BMC Womens Health       Date:  2013-03-15       Impact factor: 2.809

7.  Is it a rights violation or lack of knowledge about options? An examination of HIV counselors views on whether women infected with HIV should procreate.

Authors:  Amos Kankponang Laar
Journal:  Pan Afr Med J       Date:  2013-02-27

Review 8.  Infertility and the provision of infertility medical services in developing countries.

Authors:  Willem Ombelet; Ian Cooke; Silke Dyer; Gamal Serour; Paul Devroey
Journal:  Hum Reprod Update       Date:  2008-09-26       Impact factor: 15.610

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.